A Study of LY2599506 in Patients With Type 2 Diabetes


Tracking Information

Start Date  ICMJEDecember 2009
Estimated Primary Completion DateDecember 2010   (final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 1, 2009)
Change in hemoglobin A1c from baseline to 12 week endpoint [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
Original Primary Outcome Measures ICMJESame as current
Change HistoryComplete list of historical versions of study NCT01024244 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ICMJE 
 (submitted: December 1, 2009)
  • Change in QT interval in electrocardiogram from baseline to 12 week and 16 week endpoint [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: Yes ]
  • Change in Homeostasis Model Assessment (HOMA2) from baseline to 12 week and 16 week endpoint [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
  • Change in triglycerides, LDL, HDL, non-HDL cholesterol, total cholesterol and free fatty acids from baseline to 12 week and 16 week endpoint [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: Yes ]
  • Changes in European Quality of Life -5 dimension (EuroQol-5 dimension) from baseline to 12 week and 16 week endpoint [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
  • Change in blood pressure [ Time Frame: Baseline to 12 weeks, 16 weeks ] [ Designated as safety issue: Yes ]
  • Incidence of hypoglycemic episodes, categorized by severity and treatment group from baseline, during 12 weeks of treatment, and during 4 weeks of follow-up period [ Time Frame: Baseline, up to 12 weeks and 16 weeks ] [ Designated as safety issue: Yes ]
  • Change in body weight from baseline to 12 week and 16 week endpoint [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
  • 7 point self-monitored blood glucose (SMBG) [ Time Frame: Baseline, 4 weeks, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
  • Frequency of patients receiving reduced doses [ Time Frame: Baseline to 12 weeks ] [ Designated as safety issue: No ]
  • Percentage of patients with lipase and amylase measurements by treatment group and study visits above 2-fold upper limits of normal (ULN) [ Time Frame: Baseline to 12 weeks ] [ Designated as safety issue: Yes ]
  • Total and direct bilirubin, Alkaline phosphatase, alanine transaminase (ALT/SGPT), aspartate transaminase (AST/SGOT), gamma-glutamyl transferase (GGT): percentage of patients above 2-, 3-, and 5-fold upper limits of normal (ULN) [ Time Frame: Baseline up to 12 weeks, 16 weeks ] [ Designated as safety issue: Yes ]
  • Changes in Diabetes Treatment Satisfaction Questionnaire from baseline to 12 week and 16 week endpoint [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
  • Changes in Adult Low Blood Sugar Survey from baseline to 12 week and 16 week endpoint [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
  • Changes in Diabetes Symptoms Checklist-revised from baseline to 12 week and 16 week endpoint [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
  • Total daily dose of LY2599506 per visit [ Time Frame: Baseline, 1, 2, 3, 4, 6, 8, 10, 12 weeks ] [ Designated as safety issue: No ]
  • Pharmacokinetics LY2599506 maximum concentration (Cmax) [ Time Frame: Predose and 2 hours after dosing or predose and 4-12 hours after dosing in weeks 1, 2, 3, and 12 ] [ Designated as safety issue: No ]
  • Pharmacokinetics LY2599506 area under the concentration-time curve (AUC) [ Time Frame: Predose and 2 hours after dosing or predose and 4-12 hours after dosing in weeks 1, 2, 3, and 12 ] [ Designated as safety issue: No ]
  • Rate of hypoglycemic episodes per 30 days [ Time Frame: Baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks ] [ Designated as safety issue: Yes ]
  • Change in heart rate [ Time Frame: Baseline to 12 weeks, 16 weeks ] [ Designated as safety issue: Yes ]
Original Secondary Outcome Measures ICMJESame as current

Descriptive Information

Brief Title  ICMJEA Study of LY2599506 in Patients With Type 2 Diabetes
Official Title  ICMJEA 12-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY2599506 in Patients With Type 2 Diabetes Mellitus Treated With Diet and Exercise, With or Without Metformin
Brief Summary

The purpose of this study is to help answer the following questions:

  • To test if taking LY2599506 for 12 weeks controls blood sugar better than taking placebo for 12 weeks.
  • To evaluate the safety of LY2599506 in patients with diabetes.
  • To determine if LY2599506 has the ability to control blood sugar in patients with diabetes.
  • To determine how much LY2599506 should be given to patients.
  • To determine if LY2599506 has an effect on a patient's weight.

The study design consists of 4 study periods: a screening period, a 4-week dose adjustment period, an 8 week treatment period, and a 4-week follow up period.

Detailed Description 
Study PhasePhase II
Study Type  ICMJEInterventional
Study Design  ICMJETreatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Condition  ICMJEDiabetes Mellitus, Type 2
Intervention  ICMJE
  • Drug: Placebo
    Administered orally for 12 weeks
  • Drug: LY2599506
    Administered orally for 12 weeks
    Other Name: Glucokinase Activator
Study Arms / Comparison Groups
  • Placebo twice daily: Placebo Comparator
    Intervention: Drug: Placebo
  • 50 mg twice daily LY2599506: Experimental
    Intervention: Drug: LY2599506
  • 100 mg twice daily LY2599506: Experimental
    Intervention: Drug: LY2599506
  • 200 mg twice daily LY2599506: Experimental
    Intervention: Drug: LY2599506
  • 200 mg once daily: Experimental
    Intervention: Drug: LY2599506

Recruitment Information

Estimated Enrollment  ICMJE120
Estimated Completion DateJanuary 2011
Estimated Primary Completion DateDecember 2010   (final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Have type 2 diabetes mellitus prior to entering the trial.
  • Are currently being treated with diet and exercise therapy consistent with the local standards of medical care.
  • May be treated with diet and exercise alone or in combination with a stable of metformin for at least 3 month before entering the trial.
  • Have an hemoglobin A1c value between 7.0% and 10.0 %, inclusive.
  • Are women not of child-bearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause. Male patients will be advised to use a reliable method of birth control during the study and until 3 months after the last dose of study medication if their partner is of child-bearing potential.

Exclusion Criteria:

  • Use of insulin or any antidiabetic agent other than metformin during the 3 months prior entering the trial.
  • Have a gastrointestinal disease that significantly impacts gastric emptying or motility (for example, severe gastroparesis or pyloric stenosis), in the opinion of the investigator, or have undergone gastric bypass or gastric banding surgery.
  • Have had more than 1 episode of severe hypoglycemia within 6 months prior to entry into the study, or are currently diagnosed as having hypoglycemia unawareness.
  • Have had 2 or more emergency room visits or hospitalizations due to poor glucose control in the past 6 months.
  • Have cardiac autonomic neuropathy (for example, resting tachycardia or orthostatic hypotension), based on clinical signs, symptoms, or appropriate diagnostic testing.
  • Have cardiac disease with functional status that is New York Heart Association Class II, III or IV or a history of myocardial infarction, unstable angina, or decompensated congestive heart failure in the past 6 month.
  • Have poorly controlled hypertension (that is, mean systolic blood pressure of greater or equal than 160 mm/Hg or mean diastolic blood pressure of greater or equal than 100 mm/Hg) history of malignant hypertension, evidence of renal artery stenosis and/or evidence of labile blood pressure including symptomatic postural hypotension. Doses of antihypertensive medications must be stable for 30 days before randomization.
  • Have fed or fasting state hypertriglyceridemia (defined as >6.8 mmol/L, 600 mg/dl) at screening. If taking lipid-lowering agents, doses of these medications must be stable for 30 days prior to randomization.
  • Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or repeated alanine transaminase (ALT) levels >2.5 times the upper limit of the reference range at screening.
  • Have evidence of a significant active, uncontrolled endocrine or autoimmune abnormality, as judged by the Investigator at screening.
  • Have an active or untreated malignancy or have been in remission from a clinically significant malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.
GenderBoth
Ages18 Years to 70 Years
Accepts Healthy VolunteersNo
Contacts  ICMJE
Contact: There may be multiple sites in this clinical trial. (1-877-CTLILLY (1-877-285-4559) or1-317-615-4559
Location Countries  ICMJEUnited States,   Australia,   Puerto Rico,   Russian Federation,   Spain

Administrative Information

NCT ID  ICMJENCT01024244
Responsible PartyChief Medical Officer, Eli Lilly
Study ID Numbers  ICMJE12781, I2Q-MC-GMAH
Study Sponsor  ICMJEEli Lilly and Company
Collaborators  ICMJE 
Investigators  ICMJE
Study Director:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Eli Lilly and Company
Information Provided ByEli Lilly and Company